Certificate in Cancer Immunotherapy

SITC Graduate in Cancer Immunotherapy / SITC-G

CLICK HERE

Learning Modules

• Module 1: Basic Immunology Concepts, Updated Version Available Now (As of 10/14/2022*) 
  • This course, Module 1: Basic Immunology Concepts,will cover some of the key immunology needed to understand the rest of the certificate program.

• Module 2: Basic Cancer Immunotherapy Concepts, Updated Version Available Now (As of 11/14/2022*) 
  • This course, Module 2: Basic Cancer Immunotherapy Concepts, will cover the biological foundation of cancer immunotherapy, applying the basic immunology you learned in the last module to help lay the foundation for future topics in this program.

• Module 3: Immune Checkpoint Blockade, Available now!
  
  • This course, Module 3: Immune Checkpoint Blockade, will cover the biological foundation of immune checkpoint blockade therapies as well as diving into their clinical use.

• Module 4: Managing Immune Checkpoint Inhibitor Adverse Events, Available now!
  • This course, Module 4: Managing Immune Checkpoint Inhibitor Adverse Events, will cover the presentations, diagnosis and management of adverse events resulting from immune checkpoint inhibitor treatments.

• Module 5: Other Approaches (Cytokines, Vaccines and Immune Cell Engagers), Available now!
  • This course, Module 5: Other approaches (Cytokines, vaccines, immune cell engagers), will cover the biological foundation and clinical implementation of cytokines, vaccines and immune cell engagers as immunotherapies for cancer, including adverse event management.

• Module 6: Oncolytic Viruses and Intralesional Therapy, Updated Version Available Now (As of 11/29/2022*) 
  • This course, Module 6: Oncolytic Viruses and Intralesional Therapy, will cover the biological foundation and clinical implementation of intratumoral therapies and oncolytic viruses. 
  • This activity does not offer continuing education credit.

• Module 7: CAR T Cell and Cellular Therapy, Available now!
  • This course, Module 7: CAR T Cell and Cellular Therapy, will cover the mechanisms and clinical administration of cellular therapies for cancer, including an emphasis on adverse event management.

• Module 8: Implementing Cancer Immunotherapy in Clinical Practice, Available now!
  • This course, Module 8: Implementing Cancer Immunotherapy in Clinical Practice, will cover the practical aspects of instituting immunotherapy treatments in a clinical practice, such as education considerations, value-based care, and access to patient and provider resources.

Target Audiences

The primary target audience for the program is treating physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate will also be available to practicing, licensed NPs, PAs, and PharmDs (or RPh degree holders involved in direct clinical services), or global equivalent. The courses will be available to those who are not practicing clinicians, but they will not be eligible to earn the certificate.

Requirements

The requirements to earn the certificate include:

• Must be a treating physician (U.S. licensed MD / DO or global equivalent), or a practicing licensed NP, PA, PharmD or RPh degree holder involved in direct clinical services, or global equivalent
• Complete the coursework (all eight modules)
  • anticipated to be approximately 1 hour each, for a total of 8 hours
• Pass all end-of-module assessments
• Successfully complete a comprehensive exam covering all modules

Certificate Term

The certificate term is two years. Then, to earn a current certificate, which allows one to continue to use the SITC-G designation, an individual will need to take and pass updated coursework and assessments. If one misses the deadline for reissuance, he or she will need to retake and pass the full program.

Certificate Program Task Force

CHAIR

Robert L. Ferris, MD, PhD
University of Pittsburgh Medical Center Hillman Cancer Center

Members

Leisha Emens, MD, PhD –
University of Pittsburgh Medical Center Hillman Cancer Center
Umar Farooq, MD – University of Iowa
Silvia Formenti, MD – Weill Cornell Medicine
Sigrun Hallmeyer, MD – Advocate Medical Group
Howard Kaufman, MD, FACS –
Ankyra Therapeutics/Massachusetts General Hospital
Jose Lutzky, MD, FACP – University of Miami Sylvester Cancer Center
George Weiner, MD – University of Iowa